Teva Ruling Keeps Drug-Monopoly Lawsuit Alive Against Corcept

Corcept Therapeutics Inc. will continue litigating state-law antitrust claims that it harmed competition in the market the cortisol-lowering drug Korlym, after a federal judge ruled that a rival’s allegations were sufficient to withstand dismissal.

Plaintiff Teva Pharmaceutical Industries Ltd. properly alleged that Corcept and co-defendant Optime Care Inc. foreclosed a substantial share of the market for Korlym and its generic equivalents, Judge Noël Wise of the US District Court for the Northern District of California said in an order denying most of Corcept’s motion to dismiss.

“The standing inquiry here is correspondingly straightforward: Teva lost sales (injury) because of Defendants’ ...